<DOC>
	<DOCNO>NCT01874080</DOCNO>
	<brief_summary>The purpose study determine tablet manufacture different site bioavailability , yield similar blood levels/concentrations drug handle body similarly</brief_summary>
	<brief_title>Bioequivalence Study</brief_title>
	<detailed_description>Primary Purpose : Other : Protocol design demonstrate bioequivalence fix dose combination 5 mg Saxagliptin 1000 mg Metformin Extended Release Tablet manufacture Mt . Vernon , Indiana Humacao , Puerto Rico relative fix dose combination tablet manufacture Mt . Vernon , Indiana bioequivalence fix dose combination 5 mg Saxagliptin 500 mg Metformin Extended Release Tablet manufacture Mt . Vernon , Indiana Humacao , Puerto Rico relative fix dose combination tablet manufacture Mt . Vernon , Indiana healthy human subject feed condition</detailed_description>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Healthy male female subject , 1845 year age Body mass index ( BMI ) 18.0 30.0 kg/m2 , inclusive Women must negative serum urine pregnancy test within 24 hour prior start investigational product Any significant acute chronic medical illness Estimated creatinine clearance &lt; 60 mL/min calculate use Modification Diet Renal Disease method Current recent ( within 3 month study drug administration ) Gastrointestinal ( GI ) disease could affect absorption study drug Inability tolerate oral medication History allergies adverse reaction DPP4 inhibitor Metformin relate compound Current smoker recent ( within 6 month study drug administration ) history regular tobacco use ( positive cotinine test )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>